- In recent years, baclofen has demonstrated potential to reduce symptoms of severe AWS in people with alcoholism
- In one of a study baclofen 30mg/day (in divided dose) was given consequently and compared with another group taking diazepam. The study concluded that baclofen was comparable to diazepam in treatment of AWS.
Cochrane Recommendations
- Regarding the efficacy, one study found that both baclofen and diazepam significantly decreased the CIWA-Ar score, without any significant difference between the two interventions. The other study showed no significant difference in CIWA-Ar score between baclofen and placebo, but did show a significantly decreased dependence on high-dose benzodiazepines with baclofen compared toplacebo.
- Only one study reported safety outcomes, finding no side effects in either the baclofen group or the diazepam group
- The evidence for recommending baclofen for AWS is insufficient. We require more well-designed RCTs to prove its efficacy and safety
- Not recommended as the evidence are mixed compared to Gold standard
References:
- http://www.ncbi.nlm.nih.gov/pubmed/16490478
- http://www.cochrane.org/CD008502/ADDICTN_baclofen-for-alcohol-withdrawal-syndrome
- http://www.aafp.org/afp/2013/1101/p589.html#afp20131101p589-b37
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.